Drug Trial Radar · NCT04179409
A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.
Last checked: Nov 20, 2026Latest source record: Oct 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3
Actual
Start
Feb 18, 2020
Primary completion
Sep 1, 2021
Study completion Sep 1, 2023
Sponsor
- Lead sponsor
- Kevin FlaniganAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sarepta Therapeutics, Inc.
- First posted
- Nov 27, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an 48-week open-label study to determine the efficacy and safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 for the treatment of boys with duchenne muscular dystrophy who have a single exon duplication of either exon 45, 51 or 53, respectively. There will be weekly infusions and two muscle biopsies at baseline and at month 12.
Conditions
- Duchenne Muscular Dystrophy
Interventions
Amondys 45Drug
This drug is used to target skipping of exon 45 of the dystrophin gene.
Exondys 51Drug
This drug is used to target skipping of exon 51 of the dystrophin gene.
Vyondys 53Drug
This drug is used to target skipping of exon 53 of the dystrophin gene.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Dystrophin Expression From Baseline Following Treatment With Either AMONDYS 45 (Previously Casimersen), EXONDYS 51 (Previously Eteplirsen ), or VYONDYS 53 (Previously Golodirsen)Time frame: Baseline, 1 year
- Monitoring for the Development of Unacceptable Toxicity.Time frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nationwide Children's Hospital
Columbus, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.